Background. Recent data support that iodixanol, an iso-osmolality contrast agent, is less nephrotoxic than lowosmolality contrast agents when hydration is the only prophylactic strategy used. We evaluated the nephrotoxicity of iso-and low-osmolality contrast agents with prophylactic administration of N-acetylcysteine (NAC) along with hydration.
transient dialysis may be required, especially in high-risk patients [2] [3] [4] . The optimal strategy to prevent contrast agent-associated nephrotoxicity (CAN) remains uncertain. At present, recommendations are (1) periprocedural hydration [5] , (2) use of a low-osmolality contrast agent [6] [7] [8] , and (3) limiting the amount of contrast agent [9] . Recently, 2 additional strategies to be associated to hydration aroused considerable interest: administration of N-acetylcysteine (NAC) and the use of iso-osmolality contrast agents. Several trials and meta-analysis support the usefulness of oral NAC [10] [11] [12] [13] [14] [15] . NAC is a potent antioxidant compound that may prevent direct oxidative tissue damage by scavenging reactive oxygen species [16, 17] . Iodixanol (an iso-osmolality contrast agent) seems to be less nephrotoxic than low-osmolality contrast agents [18] . It has therefore been suggested that, although more expensive, use of iodixanol is cost-effective because the extra cost may be offset by the reduced cost of managing adverse reactions [19] . However, studies comparing isoversus low-osmolality contrast agents were conducted using hydration as the only prophylactic strategy to prevent CAN. Therefore, it is unknown whether the difference seen in the nephrotoxicity of low-and iso-osmolality contrast agents still exists when utilizing NAC plus hydration. This data may have important clinical as well as economic implications.
In order to clarify this issue, we performed a retrospective study of patients with chronic renal insufficiency who have undergone coronary or peripheral procedures with either low-or iso-osmolality contrast agents and were concomitantly treated with NAC plus hydration. Patients with diabetes mellitus were also analyzed separately.
METHODS

Patient population
This is a nonrandomized, observational study including all consecutive patients with chronic renal insufficiency (serum creatinine concentration ≥1.5 mg/dL and/or or an estimated glomerular filtration rate <60 mL/min/1.73m
2 ) [20] who had coronary and/or peripheral angiography and/or angioplasty in our institutions from January 2002 to December 2003. Most of patients of the present study have been previously reported [13, 14] . All patients received intravenous saline plus NAC before and after administration of the contrast agent. Saline (0.45%) was given intravenously at a rate of 1 mL/kg of body weight per hour (0.5 mL/kg for patients with left ventricular ejection fraction <40%) for 12 hours before and 12 hours after administration of the contrast agent [5] . NAC (Fluimucil; Zambon Group SpA, Milan, Italy) was given orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days) [13] . None of the patients received theophylline, dopamine, mannitol, or furosemide during the study. Serum creatinine, blood urea nitrogen, sodium, and potassium were measured immediately before and 48 hours after administration of the contrast agent; additional measurements were performed in all cases of significant impairment of renal function. Estimated glomerular filtration rate (eGFR) was calculated by applying the Level modified Modification of Diet in Renal Disease (MDRD) formula: (186.3 × serum creatinine −1.154 ) × (age −0.203 ) × (0.742 if female) [20] . Proteinuria was determined by an immunometric assay (NycoCard ® U-Albumin; Axus-Schiled PoCAS, Oslo, Norway). Microalbuminuria and macroalbuminuria were defined as protein excretion of 30 to 300 mg/24h and >300 mg/24h, respectively. The risk score for predicting CAN was calculated according to Mehran et al [21] .
Contrast agents
Iobitridol (Xenetin-350, 350 mg iodine/mL; Guerbet, France), a nonionic, low-osmolality (915 mOsm per kg of water) contrast agent was administered to patients of the iobitridol group. Iodixanol (Visipaque ® , 320 mg iodine/mL; Amersham Health), a nonionic, iso-osmolality (290 mOsm per kg of water) contrast agent was used in the iodixanol group. Two different cutoffs were used to define the high limit of contrast dye administered to each enrolled patient: (1) ≥140 mL [14] and (2) (5 × kg body weight) divided by serum creatinine (mg/dL): a weightand creatinine-adjusted maximum contrast dose (MCD) [9] . This limit was converted to a dichotomous variable by dividing the actual amount of contrast received by the calculated MCD to determine the "contrast ratio." If the ratio was >1 then the MCD was defined as exceeded [9] .
Follow-up
Acute contrast agent-associated nephrotoxicity was defined as an increase in the serum creatinine concentration ≥0.5 mg/dL from the baseline value 48 hours, or the need for dialysis after administration of the contrast media. Acute renal failure requiring dialysis was defined as a decrease in renal function necessitating acute hemodialysis, ultrafiltration, or peritoneal dialysis within the first 5 days' postintervention.
The rates of early (<24 h) and late (>24 hours to 7 days) reactions to contrast agent were assessed [22] . Rate of major adverse events (death, acute myocardial infarction, stroke, new or repeated coronary or peripheral revascularization and dialysis) at 12 months was assessed in order to establish the long-term impact of contrast nephropathy.
Statistical analysis
Continuous variables are given as mean ± 1 standard deviation or median and interquartile ranges (IQR). Unpaired Student t test was performed to determine differences between mean values for continuous variables when appropriate. Categorical variables were analyzed by chi-square test. Creatinine and proteinuria concentrations were not normally distributed; therefore, the nonparametric Wilcoxon and Mann-Whitney tests were used to assess differences. To test the impact of contrast agent type (that is, iobitridol and iodixanol) on rate of CAN, we used the 2 repeated measures analysis of variance ANOVA and analysis of covariance ANCOVA models after transforming creatinine levels into natural logarithm (to overcome the problem of the non-normal distribution). In the ANOVA model we considered the treatment strategy (as defined in iobitridol group and iodixanol group), time period, and time × treatment strategy interaction as fixed effects and patients as a random effect. In the ANCOVA model we put the log-creatinine concentration at 48 hours as dependent variable, treatment strategy (as defined in iobitridol and iodixanol groups) as fixed factor, and baseline log-creatinine level and the presence of diabetes mellitus as covariates. Probability values < 0.05 were considered significant. Data were analyzed with SPSS 10.0 (Chicago, IL, USA) for Windows.
RESULTS
Clinical characteristics
Two hundred and twenty-five patients were included in the analysis. The clinical and biochemical characteristics of the 225 patients in the 2 groups are shown in Tables 1  and 2 . The total amount of intravenous hydration was comparable: iobitridol group = 1798 ± 348 mL versus iodixanol group = 1805 ± 283 mL (P = 0.99). The amount of contrast agent administered was also similar in the 2 groups (iobitridol group: 167 ± 90 mL, iodixanol group 164 ± 82 mL; P = 0.61). A large volume (>140 mL) of contrast dye was administered to 48% of iobitridol group patients and 57.5% in the iodixanol group (P = 0.18). A contrast ratio >1 occurred in 26% cases in the iobitridol group and 31% cases in the iodixanol group (P = 0.54). The incidence of early and late reactions to contrast agent is reported in Table 3 .
Contrast agent-associated nephrotoxicity
Serum creatinine concentration for all patients was 1.70 (IQR 1.55-1.99) mg/dL. In the iobitridol group, serum creatinine concentration decreased from 1.70 (IQR 1.54-1.98) mg/dL at baseline to 1.53 (IQR 1.35-1.85) mg/dL 48 hours after contrast agent administration (P < 0.001). In the iodixanol group, serum creatinine concentration decreased from 1.73 (IQR 1.56-2.00) to 1.66 (IQR 1.43-1.90) mg/dL (P < 0.001). Contrast nephropathy risk score was similar in the 2 groups. Most of the patients in the 2 groups had a risk score ≤5. None had a risk score ≥11 (Table 2) . No interaction between contrast agent type and creatinine level at 48 hours after procedure was observed by the 2 repeat measure ANOVA (F = 2.27; P = 0.13) and even after including baseline creatinine level and presence of diabetes mellitus as covariates (F = 1.20; P = 0.27 by ANCOVA model). CAN (that is, increase ≥0.5 mg/dL of creatinine concentration) occurred in 4/115 patients of the iobitridol group (3.5%) and in 3/110 patients of the iodixanol group (2.7%) (P = 1.00; OR 0.58; 95% CI 0.17-3.56). No case of renal failure requiring temporary dialysis occurred. In the 23 patients with left ventricular ejection fraction <40%, renal function deterioration occurred in 1/11 (9%) in the iobitridol group and none of the 12 patients in the iodixanol group (P = 0.48). In patients given a large volume (>140 mL) of contrast media (N = 116), CAN occurred in 2/55 (3.6%) in the iobitridol group and in 1/61 (1.6%) in the iodixanol group (P = 0.60). Length of in-hospital stay (from admission to discharge) was similar in the 2 groups (iobitridol group 2.2 ± 0.9 vs. iodixanol group 2.2 ± 0.6 days; P = 1.00).
At 1-year follow-up major adverse events occurred in 26 of the 115 (22.5%) patients in the iobitridol group and in 33 of the 110 patients (30%) of the iodixanol group (P = 0.22). Rate of death (8.7% vs. 11.8%, P = 0.66), myocardial infarction (1.7% vs. 1.8%, P = 1.00), any percutaneous or surgical coronary or peripheral revascularization (10.5% vs. 14.5%, P = 0.42), and end-stage renal failure requiring dialysis (2.6% vs. 3.6%, P = 0.71) were similar in the 2 groups. Although not statistically significant, occurrence of major adverse events was higher in the 7 patients who experienced CAN (43% vs. 26%; P = 0.38). Of note, end-stage renal failure requiring dialysis at 12 months occurred in 2 of the 7 (28.5%) patients who experienced CAN versus 5 of the 218 (2.3%) who did not experienced CAN (P = 0.016; OR 17.1; 95% CI 2.65-110.4).
Diabetic patients
There were 104 diabetic patients, 49 in the iobitridol group and 55 in the iodixanol group. Twenty-three patients (22%) were receiving insulin. The principal characteristics of these patients were similar in the 2 groups and are summarized in Table 4 . In these patients, the risk score for CAN was 5.5 ± 1.8 in the iobitridol group and 5.8 ± 1.8 in the iodixanol group (P = 0.40). Urinary protein excretion was similar in the 2 groups. In particular, macroalbuminuria was observed in 12% of patients in the iobitridol group and in 13% of the iodixanol group (P = 1.0). CAN occurred in 2/49 (4.1%) in iobitridol group and in 3/55 (5.5%) in the iodixanol group (P = 1.00).
DISCUSSION
The main result of the present study is that the rate of CAN in a low-to-medium risk population does not seem to be different after the use of iobitridol or iodixanol when a prophylactic strategy of hydration plus NAC administration is systematically used.
Low-versus iso-osmolality contrast agents and nephrotoxicity
Experimental studies have provided conflicting data regarding the role of osmolality in the pathogenesis of CAN. Some studies indicated that the osmolality of the contrast agent is a major determinant of CAN [23, 24] , whereas other studies demonstrated that the nephrotoxic effect of contrast media is related to some property other than osmolality [25] . Iodixanol is a dimeric nonionic contrast agent with lower osmolality and a higher iodine ratio, but greater viscosity than most other com- monly used contrast agents. The lower nephrotoxicity of iodixanol versus low-osmolality contrast agents has been substantiated by the following characteristics: (1) the diuretic effect of iodixanol is less than that of iomeprol and ioxaglate, mostly due to the different osmolality [26] ; and (2) fractional of sodium excretion and urinary excretion of N-acetyl-b-glucosaminidase and alkaline phosphatase showed smaller increases with iodixanol than with iomeprol and ioxaglate [27] . These findings may indicate that iodixanol is less tubulotoxic than low-osmolality contrast agents. On the contrary, experimental studies in rats showed that the higher viscosity of iodixanol (11.4 mPa × sec at 37
• C vs. 10 mPa × sec of iobitridol) might cause stasis in renal tubules, worsening medullary hypoxemia [28] . Although preliminary studies showed conflicting data on the lower nephrotoxic effect of iodixanol compared to low-osmolality contrast agents [29] [30] [31] [32] , the Nephrotoxic Effects in High-Risk Patients Undergoing Angiography (NEPHRIC) trial [18] demonstrated that iodixanol is less nephrotoxic than iohexol when administered in patients with diabetes mellitus and chronic renal insufficiency. Incidence of CAN was 26% (17/65) in the iohexol group versus 3% (2/64) in the iodixanol group (P = 0.002; OR 0.09; 95% CI 0.02-0.41). In the NEPHRIC trial hydration alone was used as a prophylactic strategy. In the present study we found a very low incidence of CAN in both groups and no significant difference in CAN rate between iobitridol (3.5%) and iodixanol (2.7%) when a systematic prophylactic strategy of hydration plus NAC is utilized. Incidence of CAN in both groups is similar to that observed in the iodixanol arm of the NEPHRIC trial. Furthermore, in the subgroup of patients with diabetes mellitus, incidence of CAN was 4.1% in the iobitridol group versus 5.5% in the iodixanol group. The 4.1% rate of CAN observed in the iobitridol group is similar to that observed in the iodixanol arm of the NEPHRIC trial and very low compared to the iohexol arm (26%) of the above trial and to what reported in the literature [1, 33] .
Impact of NAC on nephrotoxicity of low-and iso-osmolality contrast agents
The prophylactic administration of NAC along with hydration may explain our different findings compared to those reported in the NEPHRIC trial. NAC, a potent antioxidant that scavenges a wide variety of oxygen-derived free radicals, may prevent contrast-associated nephrotoxicity by stopping direct oxidative tissue damage and also by improving renal hemodynamics [16, 17, 34] . Following the first observation by Tepel et al [10] , a recent metaanalysis evaluating over 800 high-risk patients enrolled in randomized controlled trials supported that NAC plus hydration significantly reduces the risk of CAN in patients with chronic renal insufficiency [15] . The antioxidant effect of NAC seems to be dose-dependent. Indeed, we recently demonstrated that a double-dose of NAC (1200 mg/day for 2 days) seems to be more effective than the standard dose [13] . NAC may prevent contrast agent nephrotoxicity, equalizing differences in the chemical or physical properties (besides osmolality) between iso-and low-osmolality contrast agents.
Late reactions
The selection of contrast agent should take into account early and late reactions. The incidence of late reactions ranges from 8% to 71% [22] . Although no contrast agent is free from these side effects, late reactions have been reported to be higher with iso-osmolality than lowosmolality contrast agents [22] . Our study confirms this previous finding of an excess number of late skin reactions following the use of iodixanol. Although the course of skin reactions appears benign, patients should be advised of this particular side effect, which may be difficult to differentiate from that related to the use of other drugs, such as clopidogrel.
Clinical implications
According to the results of the present study we can state that, when a prophylactic strategy of hydration plus NAC is utilized, the incidence of CAN in a low-tomedium risk population does not seem to be significantly influenced by the administration of whether an iso-or a low-osmolality contrast agent. This result has important clinical as well as economic implications. Contrast media accounts for 10% of all causes of hospital-acquired renal failure [1] [2] [3] [4] . CAN causes a prolonged in-hospital stay [13] and represents a powerful predictor of poor early and late outcome [2] [3] [4] . Careful preprocedural stratification has been recommended. The risk score proposed by Mehran et al [21] is simple to calculate and very useful for individual patient risk assessment. In the present study, patients who experienced CAN had a 2-fold higher risk of major adverse events and a 17-fold higher risk of requiring dialysis at 1 year. Iodixanol is more expensive than low-osmolality contrast agents. As recently suggested, this increased cost may be offset by the reduced cost of managing adverse reactions [19] . However, we did not observe any significant difference in the rate of CAN between the iodixanol and iobitridol groups. This result was also confirmed in the subgroup of patients with diabetes mellitus. According to these data, and taking into account the 2-fold higher risk of late dye-related reactions observed in the iodixanol group, we do not recommend the universal use of iodixanol to prevent CAN in the type of patients included in our study, provided an optimal prophylactic strategy of hydration plus NAC administration is followed.
Study limitations
The retrospective nature of the study represents the main limitation. The results of the present study cannot be extended to patients at high or very high risk for CAN, and all low-osmolality contrast agents.
CONCLUSION
The strategy of hydration plus NAC seems to eliminate any advantage of using the iso-osmolality versus low-osmolality contrast agents in preventing CAN in a low-to medium-risk population.
